Takeda Chemical Industries, Inc.

Kagoshima University

Tobira Therapeutics, Inc.

Yale University

Takeda Pharmaceutical Company Limited

Mitsubishi Kasei Corporation

Richter Gedeon Vegyeszeti Gyar Rt

Stichting Rega Vzw

Other

Daikin Industries, Ltd.

Toray Industries, Inc.

Taiho Pharmaceutical Company Limited

Okayama University

Sanyo-kokusaku Pulp Co., Ltd.

Nobelpharma Co., Ltd.

Masanori Baba

Naoyuki Kanzaki

Mitsuru Shiraishi

Osamu Nishimura

Masaki Seto

Hiromichi Tanaka

Yoshio Aramaki

Yuji Iizawa

Katsuji Aikawa

Erik D De Clercq

Mitsuru Akashi

Yung-Chi Cheng

Tadashi Miyasaka

Shinichi Imamura

Shohei Hashiguchi

Richard T Walker

Masaru Ubasawa

Sandor Gorog

Hidekazu Sawada

Yoshihiro Sugihara

Ken-ichi Kuroshima

Miklos Low

Miklos Nagy

Sandorne Gyorgyi

Norikazu Sakakibara

Taeko Hattori

Hiroyuki Watanabe

Yuichi Hashimoto

Jan Balzarini

Chikateru Nozaki

Dominique Schols

Masanori Ikeda

Makoto Onishi

Minoru Ono

Teruhiko Ide

Erik De Clercq

Kazuyoshi Kaminaka

Osamu Kurasawa

Naoki Miyamoto

Shiro Shigeta

Yasuaki Hanasaki

Hiromitsu Takayama

Kimio Katsuura

Nobuyuki Kato

Masatoshi Fujiwara

Tomoyuki Yokota

Midori Takeda

Robert A Davey

Yasuteru Sakurai

Tomofumi Uto

Masaaki Toyama

Takami Akagi

Prem Mohan

Rudi Pauwels

Shin-ichiro Sakai

Katsushi Ijichi

Described herein are pharmaceutical compositions capable of blocking entry of a virus into a host cell and containing one or more compounds of the general formula I or a pharmaceutically acceptable derivative thereof and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat viral infections.

Amodiaquine analogs and methods of uses thereof

The present invention pertains to an antiviral drug for severe fever with thrombocytopenia syndrome, which contains a compound represented by formula (I) or a salt thereof, or a solvate of the compound or salt (In the formula, R1 and R2 are the same or different from each other, and each represents a substituted or unsubstituted C1-10 alkyl group, R1 and R2 may form a substituted or unsubstituted 5- or 6-member ring in conjunction with an adjacent nitrogen atom, and X represent a halogen atom.)

Antiviral drug for severe fever with thrombocytopenia syndrome

It is an object of the present invention to provide a novel therapeutic agent for hepatoma viruses. Specifically, the present invention relates to an anti-hepatoma virus agent, containing as an active ingredient a compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof: (wherein Ris fluorine or hydrogen).

Anti-hepatoma-virus agent

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, Ris a 5- to 6-membered ring group which may be substituted; Xis a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; Xis a bivalent group of 1 to 4 atom; Zis a bivalent cyclic ring group or the like; Zis a bond or the like; and Ris an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

Bicyclic compound, production and use thereof

The present invention relates to novel compounds according to the general formulas I, II, III, IV or V: wherein B is nucleoside base according to the structure: and the remaining variables as defined in the specification, and pharmaceutical compositions comprising the compounds. The compounds are useful interalia as anti-viral agents in viral therapy.

Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections

A polyion complex (PIC) or a PIC nanoparticle that may be easily prepared, and that is finally disappeared in vivo due to its suitable biodegradability while exhibiting high stability in vivo, an immunotherapy agent comprising the PIC nanoparticle to which various antigen proteins or peptides may be easily conjugated or incorporated and/or which may be easily mixed with the antigen proteins or peptides, as well as a process for preparing thereof are provided. Specifically, a polyion complex (PIC) comprising a hydrophobized poly(acidic amino acid) and a basic polypeptide, a nanoparticle thereof having a particle shape, an immunotherapy agent comprising the PIC nanoparticle, as well as a process for preparing the PIC, comprising steps of introducing a hydrophobic amino acid to a poly(acidic amino acid) to prepare a hydrophobized poly(acidic amino acid), and dissolving the hydrophobized poly(acidic amino acid) prepared to a buffer, and it is mixed with a basic polypeptide dissolved in a buffer.

Polyion complex comprising hydrophobized polyamino acid and use of the same

An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein Ris H, OH, an alkoxy group, an acyl group, or a thioacyl group, Ris an acyl group, a thioacyl group, CONRR, or CSNRR(Rand Rbeing each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or Rand Rtogether may form a ring, Xand Xmay be the same or different and are each &#x2014;CRR&#x2014;, &#x2014;SiRR&#x2014; or oxygen, and Rand Rmay be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.

Therapeutic drug for adult T-cell leukemia

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, Ris a 5- to 6-membered ring group which may be substituted; Xis a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; Xis a bivalent group of 1 to 4 atoms; Zis a bivalent cyclic ring group or the like; Zis a bond or the like; and Ris an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

Use of a polyamino acid as an adjuvant; an application of a polyamino acid as an adjuvant in the production of a vaccine; a vaccine comprising a polyamino acid as an adjuvant; a biodegradable nanoparticle having a virus antigen immobilized thereon; and a vaccine comprising the biodegradable nanoparticle.

Polyamino acid for use as adjuvant

The present invention relates to compounds according to the general formula: wherein B is or and the remaining variables are defined in the specification, and compositions comprising the compounds. The compounds are useful as anti-viral agents in viral therapy.

Growing community of inventors

Kagoshima, Japan

Masanori Baba